Achieve Life Sciences Inc. has released a corporate presentation detailing its progress and strategic plans for addressing nicotine dependence in the United States. The presentation highlights the company's efforts to introduce Cytisinicline, a new treatment for nicotine addiction, marking the first potential new nicotine dependence treatment in nearly 20 years. Achieve Life Sciences aims to address a market of up to 50 million Americans who use tobacco, focusing on the significant public health crisis posed by nicotine dependence. The presentation outlines the anticipated timeline for FDA approval and product launch, with smoking cessation NDA filed and a launch expected in the second half of 2026. The company also emphasizes its competitive advantage, highlighting a well-tolerated product profile and favorable payor environment, including anticipated coverage under the Affordable Care Act. Additionally, Achieve Life Sciences is preparing for a focused launch strategy, leveraging innovative, data-driven solutions to drive adoption and future growth. You can access the full presentation through the link below.